Wave Life Sciences R&D Spending Growth & History (WVE)
Wave Life Sciences's r&d spending was $182.8M for fiscal 2025.
View full Wave Life Sciences company overviewWave Life Sciences annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $182.8M | $23.1M | +14.46% |
| 2024 | 2024-12-31 | $159.7M | $29.7M | +22.82% |
| 2023 | 2023-12-31 | $130.0M | $14.2M | +12.22% |
| 2022 | 2022-12-31 | $115.9M | −$6.0M | −4.94% |
| 2021 | 2021-12-31 | $121.9M | −$9.1M | −6.93% |
| 2020 | 2020-12-31 | $130.9M | −$44.5M | −25.36% |
| 2019 | 2019-12-31 | $175.4M | $41.0M | +30.50% |
| 2018 | 2018-12-31 | $134.4M | $55.1M | +69.50% |
| 2017 | 2017-12-31 | $79.3M | $38.5M | +94.30% |
| 2016 | 2016-12-31 | $40.8M | $31.8M | +350.68% |
| 2015 | 2015-12-31 | $9.1M | $6.7M | +278.16% |
| 2014 | 2014-12-31 | $2.4M | $475,000 | +24.74% |
| 2013 | 2013-12-31 | $1.9M | — | — |
Wave Life Sciences quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $51.3M | $7.8M | +18.00% |
| Q1 2026 | 2026-03-31 | $47.4M | $6.8M | +16.78% |
| Q4 2025 | 2025-12-31 | $52.8M | $8.2M | +18.30% |
| Q3 2025 | 2025-09-30 | $45.9M | $4.7M | +11.35% |
| Q2 2025 | 2025-06-30 | $43.5M | $3.1M | +7.62% |
| Q1 2025 | 2025-03-31 | $40.6M | $7.2M | +21.45% |
| Q4 2024 | 2024-12-31 | $44.6M | $10.6M | +31.02% |
| Q3 2024 | 2024-09-30 | $41.2M | $9.6M | +30.20% |
| Q2 2024 | 2024-06-30 | $40.4M | $7.1M | +21.25% |
| Q1 2024 | 2024-03-31 | $33.4M | $2.5M | +7.97% |
| Q4 2023 | 2023-12-31 | $34.1M | $3.0M | +9.64% |
| Q3 2023 | 2023-09-30 | $31.6M | $4.1M | +14.75% |
| Q2 2023 | 2023-06-30 | $33.3M | $3.6M | +12.04% |
| Q1 2023 | 2023-03-31 | $31.0M | $3.5M | +12.77% |
| Q4 2022 | 2022-12-31 | $31.1M | $5.3M | +20.64% |
| Q3 2022 | 2022-09-30 | $27.6M | −$3.5M | −11.29% |
| Q2 2022 | 2022-06-30 | $29.7M | −$1.9M | −6.01% |
| Q1 2022 | 2022-03-31 | $27.5M | −$5.9M | −17.74% |
| Q4 2021 | 2021-12-31 | $25.8M | −$4.3M | −14.22% |
| Q3 2021 | 2021-09-30 | $31.1M | $2.8M | +9.94% |
| Q2 2021 | 2021-06-30 | $31.6M | $157,000 | +0.50% |
| Q1 2021 | 2021-03-31 | $33.4M | −$7.8M | −18.87% |
| Q4 2020 | 2020-12-31 | $30.0M | −$19.1M | −38.87% |
| Q3 2020 | 2020-09-30 | $28.3M | −$16.3M | −36.58% |
| Q2 2020 | 2020-06-30 | $31.5M | −$10.1M | −24.34% |
| Q1 2020 | 2020-03-31 | $41.2M | $1.0M | +2.61% |
| Q4 2019 | 2019-12-31 | $49.1M | $9.3M | +23.41% |
| Q3 2019 | 2019-09-30 | $44.6M | $11.7M | +35.62% |
| Q2 2019 | 2019-06-30 | $41.6M | $9.1M | +27.83% |
| Q1 2019 | 2019-03-31 | $40.1M | $10.9M | +37.39% |
| Q4 2018 | 2018-12-31 | $39.8M | $14.4M | +56.92% |
| Q3 2018 | 2018-09-30 | $32.9M | $12.8M | +63.59% |
| Q2 2018 | 2018-06-30 | $32.5M | $13.4M | +70.38% |
| Q1 2018 | 2018-03-31 | $29.2M | $14.5M | +98.07% |
| Q4 2017 | 2017-12-31 | $25.4M | $11.4M | +81.27% |
| Q3 2017 | 2017-09-30 | $20.1M | $6.4M | +46.84% |
| Q2 2017 | 2017-06-30 | $19.1M | $10.7M | +127.39% |
| Q1 2017 | 2017-03-31 | $14.7M | $10.0M | +211.23% |
| Q4 2016 | 2016-12-31 | $14.0M | $10.5M | +303.55% |
| Q3 2016 | 2016-09-30 | $13.7M | $11.6M | +541.93% |
| Q2 2016 | 2016-06-30 | $8.4M | $6.6M | +354.11% |
| Q1 2016 | 2016-03-31 | $4.7M | $3.1M | +194.71% |
| Q4 2015 | 2015-12-31 | $3.5M | — | — |
| Q3 2015 | 2015-09-30 | $2.1M | $1.5M | +264.44% |
| Q2 2015 | 2015-06-30 | $1.9M | — | — |
| Q1 2015 | 2015-03-31 | $1.6M | — | — |
| Q3 2014 | 2014-09-30 | $585,000 | — | — |
Wave Life Sciences r&d spending trends
Over the last five fiscal years, Wave Life Sciences's r&d spending increased from $130.9M to $182.8M, a change of $51.8M. The latest reported quarter, Q2 2026, shows $51.3M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Wave Life Sciences source filings ↗